Aurobindo Pharma Arm to Acquire Additional 20% Stake in Chinese Joint Venture Company

MT Newswires Live2025-12-23

Helix Healthcare, a wholly-owned subsidiary of Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804), has entered into a binding agreement to acquire an additional 20% stake in its joint venture Luoxin Aurovitas from its part China's Shandong Luoxin Pharmaceutical Group Stock, for $5.1 million, according to a Tuesday filing to the Indian stock exchanges.

With this, Helix's shareholding in Luoxin Aurovitas will increase to 50%, with the right to acquire the remaining 50% stake by December 2029 at an agreed price of $18.9 million.

The object of acquisition is to expand the manufacturing to economies of scale by adding two high-speed lines and cater market demand.

The company's shares were down nearly 1% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593978496?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-23 17:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593978496","market":"us","top_or_hot":-1,"title":"Aurobindo Pharma Arm to Acquire Additional 20% Stake in Chinese Joint Venture Company","media":"MT Newswires Live","content":"<html><body><p> Helix Healthcare, a wholly-owned subsidiary of Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804), has entered into a binding agreement to acquire an additional 20% stake in its joint venture  Luoxin Aurovitas from its part China's <a href=\"https://laohu8.com/S/08058\">Shandong Luoxin</a> Pharmaceutical Group Stock, for $5.1 million,  according to a Tuesday filing to the Indian stock exchanges.</p><p>With this, Helix's shareholding in Luoxin Aurovitas will increase to 50%, with the right to acquire the remaining 50% stake by December 2029 at an agreed price of $18.9 million.</p><p>The object of acquisition is to expand the manufacturing to economies of scale by adding two high-speed lines and cater market demand.</p><p>The company's shares were down nearly 1% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aurobindo Pharma Arm to Acquire Additional 20% Stake in Chinese Joint Venture Company</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAurobindo Pharma Arm to Acquire Additional 20% Stake in Chinese Joint Venture Company\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-23 17:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Helix Healthcare, a wholly-owned subsidiary of Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804), has entered into a binding agreement to acquire an additional 20% stake in its joint venture  Luoxin Aurovitas from its part China's <a href=\"https://laohu8.com/S/08058\">Shandong Luoxin</a> Pharmaceutical Group Stock, for $5.1 million,  according to a Tuesday filing to the Indian stock exchanges.</p><p>With this, Helix's shareholding in Luoxin Aurovitas will increase to 50%, with the right to acquire the remaining 50% stake by December 2029 at an agreed price of $18.9 million.</p><p>The object of acquisition is to expand the manufacturing to economies of scale by adding two high-speed lines and cater market demand.</p><p>The company's shares were down nearly 1% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JYNT","symbol_name":"The Joint Corp.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2593978496","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593978496","pubTimestamp":1766483874,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Helix Healthcare, a wholly-owned subsidiary of Aurobindo Pharma , has entered into a binding agreement to acquire an additional 20% stake in its joint venture  Luoxin Aurovitas from its part China's Shandong Luoxin Pharmaceutical Group Stock, for $5.1 million,  according to a Tuesday filing to the Indian stock exchanges.With this, Helix's shareholding in Luoxin Aurovitas will increase to 50%, with the right to acquire the remaining 50% stake by December 2029 at an agreed price of $18.9 million.The object of acquisition is to expand the manufacturing to economies of scale by adding two high-speed lines and cater market demand.The company's shares were down nearly 1% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"JYNT":"The Joint Corp.","BK4185":"保健护理机构"},"translate_title":"Aurobindo Pharma Arm将额外收购中国合资公司20%股份","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JYNT":1.5},"content_text":"Helix Healthcare, a wholly-owned subsidiary of Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804), has entered into a binding agreement to acquire an additional 20% stake in its joint venture  Luoxin Aurovitas from its part China's Shandong Luoxin Pharmaceutical Group Stock, for $5.1 million,  according to a Tuesday filing to the Indian stock exchanges.With this, Helix's shareholding in Luoxin Aurovitas will increase to 50%, with the right to acquire the remaining 50% stake by December 2029 at an agreed price of $18.9 million.The object of acquisition is to expand the manufacturing to economies of scale by adding two high-speed lines and cater market demand.The company's shares were down nearly 1% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593978496","isCrawlerRequest":true}